The study is based on the observation of 584 patients (pts) with malignant lymphomas (Morbus Hodgkin 248, Non Hodgkin Lymphoma of favorable histology 2o3, of unfavorable histology 133), who had regular follow up's from 1974-1983. 315 of these pts attained a complete remission ( 169, 64,82 respectively). Io8 pts suffered from a relapse (61,22,25). 68% of these pts had symptoms directing to the relapse (62,77,76%). 33% palpated the tumor themselves (36,41,2o%). 2o% showed specific symptoms like local pain or lymphedema (13,13,44%). 15% suffered from general symptoms like B-symptoms (13,13,12%). Regarding the 32% of the pts without symptoms: the relapse was diagnosed by clinical examination in Io%(11, 9,8%). ~fne routinely taken chest x ray showed the relapse in 8% (Io,9,4%), the sonography in 7% (Io,5,4%). in 6% the relapse was discovered by other investigations (7,o,8%). At the time of the relapse the following laboratory findings were striking: 49% of pts with M. H. had a leucocytesis, in 7o% an elevated ESR, in 58% the alpha-2-globulin fraction was increased over Io%. Pts with unfavorable ~L showed in 6o% an elevated ESR and LDH, in 46% the alpha-2-globulin fraction was increased. Our study shows that the history and the clinical examination are the most important parameter recognizing a relapse. Chest x ray and sonography show only in 8 or 7% the relapse. The laboratory findings are less important except the ESR, the LDH and the alpha-2-globulin fraction. An EBNA positive B-cell line (GL 134) was established from bone marrow cells of a 43-year-old patient with advanced Hodgkin's disease. These cells are EBV nonproducers and express the B-cell marker B-I. In addition to a functional rearrangement of Ig-genes and expression of surface IgM/x, GL 134 cells show rearrangement but no expression of the chain genes of the T cell antigen receptor. Thus, this cell line, although phenotypically a mature B-cell, has a mixed T/B cell genotype. Further, this cell line constitutively expresses low levels of IL-2 receptors. Treatment of GL 134 with PMA not only resulted in an increase of Tac-positive cells but also enhanced Tac-antigen density on cells already positive stained with anti-Tac MoAb. IL-2 treatment also enhanced the expression of Tac-binding sites on positive cells, whereas both interferon-y and PHA had no effect. The expression of high affinity IL-2 receptors on GL 134 cells and the enhancement of IL-2 receptor by PMA was confirmed by l.) specific binding of ~2~I-IL-2; 2.) IL-2 absorption studies and 3.) Northern blot analysis. These data reveal that GL 134 expresses an average of I000 and 3000 high affinity receptors/cell (kD = I0 -z~) when unstimulated and upon PMA-stimulation, respectively. Although GL 134 cells are capable to proliferate in the absence of IL-2, the enhanced growth rate in the presence of IL-2 indicates that IL-2 exerts functional activity.
An EBNA positive B-cell line (GL 134) was established from bone marrow cells of a 43-year-old patient with advanced Hodgkin's disease. These cells are EBV nonproducers and express the B-cell marker B-I. In addition to a functional rearrangement of Ig-genes and expression of surface IgM/x, GL 134 cells show rearrangement but no expression of the chain genes of the T cell antigen receptor. Thus, this cell line, although phenotypically a mature B-cell, has a mixed T/B cell genotype. Further, this cell line constitutively expresses low levels of IL-2 receptors. Treatment of GL 134 with PMA not only resulted in an increase of Tac-positive cells but also enhanced Tac-antigen density on cells already positive stained with anti-Tac MoAb. IL-2 treatment also enhanced the expression of Tac-binding sites on positive cells, whereas both interferon-y and PHA had no effect. The expression of high affinity IL-2 receptors on GL 134 cells and the enhancement of IL-2 receptor by PMA was confirmed by l.) specific binding of ~2~I-IL-2; 2.) IL-2 absorption studies and 3.) Northern blot analysis. These data reveal that GL 134 expresses an average of I000 and 3000 high affinity receptors/cell (kD = I0 -z~) when unstimulated and upon PMA-stimulation, respectively. Although GL 134 cells are capable to proliferate in the absence of IL-2, the enhanced growth rate in the presence of IL-2 indicates that IL-2 exerts functional activity.
Div. Hematology/Oncology, Dept. of Medicine, University of G~ttingen, Robert-Koch-Str. 40, 3400 G~ttingen, F.R.G. (Bieber et al., Clin. Exp. Immunol. 29 (3), 365, 1977) . We could demonstrate a similar RIF-activity in the supernatant of the in vitro HD-tumor-cell-line L428 (Schaadt et al., Int. J. Cancer 26, 723, 1980 Rearrangements of immunoglobulin-(Ig) and T-cell receptor (TCR) genes have been shown to be specific and sensitive markers for lymphoid tumors of T-or B-cell lineage. We here report a case of a centrocytic-centroblastic Non-Hodgkin's lymphoma (NHL) with involvement of the liver and the bone marrow. Interestingly, focal conversion into a more aggressive centroblastic cell type was found in circumscribed areas of the spleen. We extracted the DNA from bone marrow and four macroscopically different sites of the spleen (A,B,C,D). The DNA was examined by Southern blot analysis using 32p-labelled cDNA probes specific for the Ig heavy chain J region genes (JH) and the TCR B-chain gene (TB). Hybridization of EcoR I digested DNA with the JH-probe DNA revealed the germline 17 kilobase pair (kb) fragment and one clonally rearranged fragment of 4.2 kb in all five biopsy specimen. Two additional bands were observed at 22.3 kb and 7.9 kb in A, indicating the existence of a second distinct neoplastic B-cell clone at this site. In D and in the bone marrow yet another additional 2.0 kb fragment occurred indicating a third entity type of B-cell tumor. The existence of 3 distinct B-cell tumors was confirmed by Southern blot analysis of Ig light chain gene rearrangements using C~ and C x cDNA probes. In addition, using the -chain cDNA probe we also observed clonal TCR gene rearrangements in all biopsy-sites investigated. These TCR rearrangements may either represent a separate neoplastic T-cell clone or, more likely, result from aberrant DNA rearrangements in the neoplastic B-cell clones.
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ROSETTE INHIBITING FACTOR (RIF) PRODUCED BY HODGKIN-CELL LINES I.Katay, E.Zittlau, H. Burrichter, M. Schaadt, V.Diehl Decreased SRBC-rosette formation of peripheral T-cells is a well known phenomenon in Hodgkints disease. From extracts of involved spleens of Hodgkin's disease (HD)-patients a rosette inhibiting factor (RIE) has been dete~ted and related to the low-density lipoprotein (LDL)-fraction
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